Compare IDEXX Laboratories, Inc. (IDXX) vs Marriott International Inc (MAR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Marriott International Inc — how do they compare? IDEXX Laboratories, Inc. trades at $518.59 (market cap $40.43B), while Marriott International Inc trades at $363.26 (market cap $94.16B). The key difference: Marriott International Inc is far larger — about 2.3× IDEXX Laboratories, Inc.'s market cap, and Marriott International Inc pays a 0.81% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Marriott International Inc for 164 Days on average.
| IDXX | MAR | |
|---|---|---|
Market Cap | $40.43B | $94.16B |
Volume | 692,164 | 996,176 |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $402.54 |
52-Week Low | $504.70 | $259.04 |
Typical Hold Time | 46 Days | 164 Days |
Enterprise Value | $41.32B | $111.47B |
Dividend Yield | — | 0.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $517.47, up 2.13% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and expanded diagnostic platforms highlight growth initiatives, while analyst consensus remains bullish with a $665 price target representing 28.5% upside potential.
The outlook remains positive given consistent earnings beats and expanding veterinary diagnostics market share. Key risks include FX headwinds, weaker U.S. vet visits, and premium valuations at 36x P/E. Institutional ownership trends show mixed activity with recent insider selling, but long-term growth drivers in pet healthcare innovation support the bullish analyst stance.
Marriott International (MAR) trades at $356.5, down 1.32% on the day, with a bullish technical signal supported by moving averages. Revenue grew to $26.19B in 2025, with a net income margin of 9.62%. Recent earnings beat expectations in Q1 and Q2 2026, while Q3 results are pending. The company maintains strong cash flow from operations at $3.21B and announced a dividend of $0.73 per share payable in September 2026.
The outlook is positive with a consensus price target of $386.71, implying upside. Risks include high debt levels and competitive pressures. Analyst sentiment is mixed with 44% buy ratings, but institutional interest remains strong, supporting a cautiously optimistic view for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →
